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Immunotherapy in lung cancer
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Summary More research and new treatment options are needed in all stages of lung cancer. To this end immunotherapy needs a revival in
view of recent improved technologies and greater understanding of the underlying biology.
In this review we discuss mechanisms of tumour immunotherapy, non-specific, specific and adoptive, with particular reference to a direct
therapeutic action on all subtypes of lung cancer.
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CURRENT TREATMENTS IN LUNG CANCER
Lung cancer remains the leading, cause of cancer death in Western
countries (Boringa et al. 1993) with more than half a million new
cases diagnosed annually worldwide. including, 40 000 in the UK.
About 80% of these tumours are of non-small-cell histological
type. including squamous (40%7). adeno- (40%). and large-cell
carcinoma (20%). The 5-year sur-vival of patients with non-small-
cell lung cancer (NSCLC) is stage related and remains poor across
all stages at about 12%. The treatment of choice for NSCLC is
surgery. but only 20% of tumours are suitable for potentially
curative surger- (Hoffman et al. 1980). Small-cell lung cancer
accounts for the remaining 2'0% of lung cancer and. despite
displaying initial chemosensitivitv. cure is achieved in onlv a
minonty of patients.
How can survival be improxved in lung cancer'? Different strate-
gies have been employed to improve the outcome. Despite the
suggested benefit ofadjuvant chemotherapy (NSCLC Group. 1995).
the role ofadjuvant therapy in operable disease awaits confirmation
in large adjuvant trials. The value of preoperatixe (neoadjuvant)
chemotherapy in NSCLC stage I. H and [Ila lung, cancer is currently
the focus of large randomized trials. including, the MRC LU22
national study. The interest in this approach comes from the encour-
aging positive effect of this treatment in two randomized studies
(Rosell et al. 1994: Roth et al. 1994). which have shown improved
survix al in patients treated with chemotherapy before surgery
compared with suryerv in resectable stage IILA disease. In unre-
sectable stage III disease there is accumulatincg evidence to support
the use of chemotherapy before local treatment (radiotherapy or
surggery). with trials show ing a small survival benefit with the
combined approach and improxed quality of life compared with
local treatment alone (Sause et al. 1995: Cullen et al. 1997). For
advanced patients. chemotherapy in stage Illb and IV disease
reduces the risk of death by 27% with a survival benefit of 10%c at
1 ear. compared with best supportive care (NSCLC Group. 1995).
For small-cell lung cancer (SCLC) there is some optimism that
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more patients with limited disease will be cured w%ith dose-
intensixe chemotherapy treatment (Thatcher et al. 1997). This
approach is being inx estigated in randomized trials. However. the
problem of maintaining a chemotherapy-induced remission
remains and needs innoxvatixve approaches.
As in all types of lung cancer current treatment options are
limited: there is thus a need to explore new treatments and
with improved technology look again at older treatments such
as immunotherapy. This systemic anti-tumour approach with low
toxicity could form part of a panoply of future treatments in
lung cancer with chemotherapy used against micrometastases.
radiotherapy or surgery against local disease and possibly
immunotherapy for maintenance ofremissions.
TUMOUR IMMUNOLOGY
Cancer cells differ from normal cells both qualitatively and quan-
titativelv. These differences are due to abnormal alycosxlation of
surface proteins. expression of viral. mutated or overexpressed
oncogene products or differentiation anticens (Boon. 1997:
Wevnants. 1997). Both the innate (natural killer (NK) cells.
macrophages and granulocytes). and the specific arms (T and B
cells) of the immune system can recognize these tumour-specific
or -associated antigens (TS/AA). NK cells that detect abnormal
gylvcosylated proteins are efficient at clearing low tumour load.
especially blood-borne micrometastases. and kill cells that express
a low level of HLA class I molecules. On the other hand. T cells
only recognize and are stimulated by a high level of HLA mole-
cules. They interact via their T-cell receptor with a specific peptide
antigen presented on a groove of an HLA molecule. This is the
first signal delivered to T cells. For T-cell activation to take place.
a second signal has to be delivered via lvmphokines such as inter-
leukin (IL-2) or an interaction betwxeen the T-cell molecules (e.g.
CD28) and co-stimulatory molecules (B7.1 ) on the antigen
presenting cell (APC) (Schwartz et al. 1992). Usually. these
sianals are delivered via professional APC-like dendritic cells.
The fact that tumour cells are different from normal cells is not
enough for efficient tumour control and. during the past few years.
progress has been made in understandinc the immunological
escape mechanisms of tumour growth. T cells. which has-e the
capacity of immunological memory (their response is amplified at
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Table 1 Randomized adjuvant BCG in NSCLC
Reference Trial design No. of pabents Comments
Jansen (1978) Intradermal 54 Improved DFI in BCG group
Pouillart (1978) Intradermal 55 Improved survival (stage 1)
Edwards (1979) Subdermal 500 No benefit
Miller (1979) Oral 308 No benefit
McKneally (1981) Intrapleural 169 Improved survival (stage 1)
Mountain (1981) Intrapleural 473 No benefit
Millar (1982) Intradermal 92 No benefit
Ludwig Group (1986) Intrapleural 407 Improved DFI in BCG group. No survival difference
a second antigen encounter). are pixotal for any specific immune
response either because they mediate the killing of the tumour
cells as in the case of cxtotoxic T lymphocytes CTLs) or because
thev secrete cvtokines. as both T helper and CTLs do. and regulate
NK and CTL actix-ation and antibody production by B lympho-
cxtes. T-cell anergy to tumour cells could occur from the absence
oftumour-specific antigens. defective antigen presentation or lack
ofco-stimulator- signals (Pardoll et al. 1993). Lack of tumour cell
killing by CTLs could also occur if the recognition of the tumour
cells by CTLs is impossible because of the lack of antigen
presentation bv HLA molecules. Tumour cells can probably dow-n-
regulate the expression of such molecules (Doyle et al. 1985:
Korkolopoulou et al. 1996 . Tumours also secrete immuno-
suppressi-e factors that mav have a negatixe effect on T cells
(Yoshino et al. 1992). e.g. SCLC cells secrete transforming growth
factor beta (TGF)-, (Fischer et al. 1994) and NSCLC cells secrete
a type-2 cytokine pattern (see beloxx) (Huang et al. 199$).
Two main approaches are used to target TS/AA for tumour
killing. The first is active immunotherapy. which aims to boost the
anti-tumour immune response of the patient. using for example
a therapeutic tumour vaccine. The second is passixve immuno-
therapy. x-hich bypasses the patient's immune system bv admini-
stration of tumour-specific antibodies or T cells. The tx o
approaches are not mutually exclusive and can be syner2istic. In
addition. a complex network of cvtokines and cells regulate the
immune response and any immune therapx that can influence any
part of it (antigen presentation. T-cell or antibody response.
cvtokine production) could in theorv have an effect on tumour
g-rowth. Cvtokines are arbitrarily diVided into type 1 [IL-2. inter-
feron gamma (IFN-y). IL-12]. w-hich promotes T-cell response.
and type 2 (IL-4. 5. 6 and 10). which promotes antibody response
(Romagnani et al. 1997). It is thought that tiltinc the balance
towards a type 1 response is beneficial in the context of solid
tumours but this rule is too simple to fit all situations. Therefore.
non-specific immunomodulators that could modifx the quality and
the intensity of an immune response could help boost an anti-
tumour effect.
IMMUNOTHERAPY IN LUNG CANCER
Non-specific immunostimulants
There hax e been sexeral randomized clinical trials using the
bacille Calmette-Guerin (BCG) -Xaccination in NSCLC Awith
various administration schedules (Table 1). These trials reported
mixed but mainly negatixve results. Although the initial tnrals by
McKneally et al 1981 ) showed a statistical survival benefit for
the Xaccinated arm. subsequent trials failed to shox- anx sur ix al
adxantage. Similarly in SCLC. BCG x-accination following, four
cycles of chemotherapy shoxed no benefit in terms of complete
response. disease-free survival or surnival (Maurer et al. 1985).
We are at present testing in lung cancer patients the use of
MvNcobacterium *vaccae (MV). a heat-killed preparation dex oid
of toxicity. with a particular interest in combininc this approach
wxith chemotherapy - the rationale being that specific tumour
activity may be seen after release of tumour antiaens by
chemotherapy combined xxith non-specific immunostimulation
by MV (O'Brien et al. 1997).
The Ludwia Lung Cancer Group (1985) studied the administra-
tion of intrapleural Corvnebactenium parnum in a randomized
phase III trial of 475 patients with resectable lunc cancer. The
treated group had a significant decrease in survival. Lexramisole is
used in association w-ith 5-fluorouracil (5-FUI in colon cancer but
appears. oxerall. to make the outcome worse in lung cancer. It has
been administered in different settings as shox-n in Table 2.
EL-2 used alone or in combination xxith other cvtokines or
lymphokine-actixated killer (LAK) cells in phase II trials in
NSCLC has induced some responses (Table 3). In the Eastern
Co-operative Oncologx group trials. IL-2 xxas used alone or with
IFN'-P: only 3 out of 73 patients showed a response. x ith a median
sunrixal of 35.6 w-eeks and no added adxantage xxith IFN-f
(Kriegel et al. 1991). Lissoni et al (1994) randomized 60 patients
xith advanced cancer to receixe low--dose IL-2 and melatonin
(pineal immunomodulating hormone) or cisplatin and etoposide
chemotherapy. Although the response rates were not significantly
different (24% and 19%7 respectixely). the mean progression-free
period and percentage survival xxere significantly different at 1
Xear in favour ofthe immunotherapy arm.
The use of LFN alone has not demonstrated activit- against
NSCLC. but synergy has been proposed between interferon and
chemotherapy (Bou-man et al. 1990). Phase II studies ofinterferon
and chemotherapy showed response rates comparable wvith
chemotherapy alone wxith acceptable toxicity (Table 4A. Phase III
trials usin2 LFN alone or IFN and chemotherapy in NSCLC are
shown in Table 5. These studies showed no statistically significant
difference in time to progression or surnix al.
Randomized trials have examined the use ofrecombinant IFN-a
as maintenance therapy following response to chemotherapy in
SCLC (Table 6). All these studies shoxxed no surnixal improxe-
ment for the IFN arm except for one study by Mattson et al ( 1992).
In this study. 237 patients were randomized following chemo-
therapx and radiotherapy treatment to no treatment or maintenance
treatment x ith lEN-ax. A statistically significant difference in
long-term sun-ix al and surnixval in limited stage disease xxas found
in faxour of the immunotherapy group. In conclusion. the concept
of merely boosting the immune svstem without presentation of
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Table 2 Results of Levamisole tnals in treatment NSCLC
Investigator Study design No. of patents Results
Study Group for Bronchogenic Operable NSCLC + levamisole 111 Trend towards improved survival with
Carcinoma (1975) levamisole
Amery (1978) Levamisole administered pre- and post-operativety 211 Trend towards improved survival with
levamisole
Wnght (1978) Operable NSCLC: intrapleural BCG levamisole 100 No benefit
Anthony (1979) As above 318 significantly poorer survival
Pines (1980) Inoperable squamous cell lung cancer 50 No benefit
BCG and levamisole following RT
Davis (1982) Advanced NSCLC chemotherapy + levamisole 381 No benefit
Holmes (1985) Operable NSCLC: surgery ± CT or BCG 130 Decreased survival with levamisole
and levamisole
Herskovic (1988) Stage II and 1II. surgery + RT levamisole 74 No benefit
Perez (1988) Inoperable NSCLC; radiation levamisole 227 Decreased survival with levamisole
Table 3 IL-2 in NSCLC
Reference Agents used No. of pabents Results
West (1987) IL-2 continuous infusion 5 1PR
Rosenberg (1989) IL-2. IL-2/LAK or IL-2/1NF 7 NR
Yang(1990) IL-2/TNF 16 1 PR
Jansen (1992) IL-2/lFN-a 11 NR
Scudelett (1993) IL-2 intralesional and systemic 8 2 PR
Lissoni (1993) IL-21melatonin 9 2 PR
Ardizzoni (1994) IL-2 continuous infusion 11 NR
IFN-a. recombinant alpha interferon; IL-2. interieukin 2: TNF, tumour necrosis factor LAK. Iymphokine activated
killer cell: PR. partial response: NR, no response
Table 4 Phase II, interferon and chemotherapy in NSCLC
Reference IFNVtype/dose/schedule CTX sequence Patient no Response/cornments
Bowman (1990) IFN-a Cisplatinum 60 Response rate 260vo
3 MU TIW or
5 MU TIW
Mandans (1993) IFN-a Carboplatin 44 Response rate 37%o
9 x loe MU TIW
Garaci (1995) IFN-x Cisplatin. etoposide and 56 Overall response rate
thymosin alpha 43%O. two CR
Kataja (1995) IFN-a Cisplatin 100 Overall response rate 33%a
9 x 1O, units TIW
Silva (1996) IFN-a Cisplatin. mitomycin C. 35 Overall response rate
3 x 106 unit D,-D vindesine 51o comparable with
chemotherapy
TIW, three times a week: IFN-a. interferon alpha; MU, million unit.
antioens is probably the reason for the overall lack of success of
these approaches.
SPECIFIC IMMUNOTHERAPY
Giving lung tumour-specific or -associated antigens (TS/AAs) has
been tested using either irradiated autologous or allogenic tumour
cells, tumour lysates and soluble tumour antigens. usually with an
immunological adjuvant such as BCG. Studies of active specific
immunization trials in lung cancer are shown in Table 7. In 1974
Hollinshead et al (1987) reported isolation oflung cancer tumour-
associated antigen (TAA). A phase H study (Stewart et al. 1976)
randomized patients with resectable NSCLC to receive either
soluble TAA in complete Freund's adjuvant (CFA). TAA and
methotrexate or no treatment post operatively. There v as a signifi-
cant improvement in sun-is-al (78%7 at 5 years) in favour of
immunotherapy or chemoimmunotherapx ox er no treatment.
Hollinshead et al (1987) reported cumulative experiences of5-year
survivals ofpatients entered into a phase H trial and two phase m
trials of specific TAA immunotherapy. Five-year survixal differ-
ence in 234 stage I and stage H NSCLC was 69% for active
immunotherapy group vs 49%7 for control (P = 0.0002). Follow-ing
on. a randomized trial using the same TAA was conducted. A total
of 86 patients with stage I and II squamous cell carcinoma were
randomized to no treatment. CFA alone or CFA + TAA w-ith a
survixal of 34.5%. 53.6%7 and 75% respectively at 5 years. The
median sunival was significantly different in favour of the
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Table 5 Randomized trials of interferon in NSCLC
Reference Design No. of pabents Results
Ardizzoni (1993) Cisplatinum/epirub.cin/cyckophosphamide 182 Increase response rate but no improvement
or CEP + IFN-a in DFS or OS
Cinaco (1995) Preoperative (mitomycin, vinblastine, 110 No significant difference in DFS or OS
cisplatinum) alone or cisplatinum.
etoposide. alpha thymosin and IFN-a
Ardizzoni (1995) Mitomycin C, ifosfamide, cisplatinum 93 No significant difference in DFS or OS
alone (MIP) or MIP and IFN-a
cisplatinum and carboplatinum
Salvati (1996) Ifosfamide alone or ifosfamide followed by 22 No improvement in DFS or OS
thymosin alpha and low dose IFN-a
DFS. disease-free survival; OS, overall survival.
Table 6 Acvity of IFN as maintenance in small-cell lung cancer
Reference Design No. of patients Results
Mattson (1992) CT + RT -- CR or PR randomize to 237 Statistically significant difference in long-term
natural IFN-a or observation survival and survival in limited group disease
in favour of immunotherapy group
Jett (1994) Chemotherapy + RT -* randomized to 120 Time to progression and survival inferior in
observation, or IFN patients treated with IFN
Tummarello (1994) Chemotherapy -* PR or CR 75 No difference in response duration or survival
randomized to IFN-a or observation
Ke4ty (1995) LUmited stage SCLC, following CR 171 No proklngation of response duration or
randomized to observation or IFN-a survival
CR. complete response: CT. chemotherapy: IFN, interferon: RT. radiotherapy: r. recombinant.
Table 7 Randomized active vaccination trial in NSCLC
Referen Trial design No. of pabents Comments
Stewart (1976) Control, TM, TAA and MTX 58 Improved DFI and overall survival
Perlin (1980) No Rx. BCG alone, 51 Trend in favour of immunotherapy
allogenic tumour cells + BCG
Souter (1981) No Rx vs intradermal injecbon of 80 No survival difference
autologous tumour cells and
C. parvum
Stack (1982) No Rx vs Autologous tumour cells 83 No survival difference
and BCG
Hollinshead (1987) No Rx, CFA alone. CFA + TAA 243 Survival advantage for immunotherapy arm
(see text)
Price-Evans (1987) No Rx vs irradiated autologous 120 No survival difference
cells and BCG
Takita (1991) No Rx, CFA alone 85 Survival advantage in immunotherapy group
TM + CFA
TM. tumour-associated antigen; MTX, methotrexate: CFA, complete Freund's adjuvant.
immunotherapy groups (38 months. 71 months. 106 months
respectively) (Takita et al. 1991). More recently. Carbone and his
colleagues (Gabrilovich et al. 1997) have vaccinated lung cancer
patients with peptides encoding mutated ras and p53 oncogene
products. They are using the dendritic cell vaccination approach:
dendritic cells are purified from cancer patients loaded with the
specific peptide antigens and reinfused intravenously to the
patient. The rational behind this approach is that dendritic cells are
professional APCs. w%hich express high levels of co-stimulatorv
molecules and HLA molecules and so an efficient T stimulation
should follow after dendritic cell vaccination.
ADOPTIVE IMMUNOTHERAPY
Rosenberg et al (1986). pioneered the use of tumour-infiltrating
lymphocytes (TILs) and showed that adoptively transferred TILs
exerted anti-tumour activity in patients with cancer. The ability of
IL-2 to expand these cells in vitro made such an approach feasible.
The initial few small trials that used adoptive immunotherapy
alone or in combination wvith IL-2 in advanced lung cancer.
demonstrated the feasibility of such an approach (Bemstein et al.
1989: Kradin et al. 1989: Faradji et al. 1991). A more recent study
(Kimura et al. 1996) used adoptiv e immunotherapy in 82 patients
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following curative resection. The patients were randomized to
receive IL-2 and LAKs following two courses of combination
chemotherapy (cisplatin, vindesine and mitomycin) or
chemotherapy alone. The 5- and 7-year survival rates of the
chemo-immunotherapy group and chemotherapy group were
58.2% and 31.5% respectively in stage H and IIIA patients. This
difference was statistically significant (P=0.0038). In patients
undergoing non-curative resection, Kimura et al (1995) reported a
survival benefit for the immunotherapy arm (IL-2 and LAK)
following randomization of 105 patients to chemotherapy, radio-
therapy or immunotherapy. The 7-year survival rate was greater in
the immunotherapy group compared with the chemotherapy and
chemo-radiotherapy groups (39.1%. 12.7%, P < 0.01).
FURTHER AVENUES FOR IMMUNOTHERAPY
The recent advances in tumour antigen characterization will
encourage the development of more standardized anti-tumour
vaccines. For example, the identification ofa series ofmelanoma-
specific gene products termed MAGEs has raised the hopes that
similar specific antigens can be found in other tumours. Indeed.
some of the MAGE antigens are expressed in about 40% of
NSCLCs (Weynants et al, 1994)
Another approach is to provide the TS/AA via irradiated whole-
cell tumour vaccines. A multitude of preclinical studies have
shown that ex vivo transfection of cytokine genes [e.g. IL-2.
granulocyte-macrophage colony-stimulating factor (GM-CSF)]
and co-stimulatory molecule genes can augnent the immuno-
genicity of the cell vaccine in vivo. This is improved by gene
combination. e.g. B7.J and IL-2 genes (Gaken et al. 1997) or GM-
CSF and IL4 (Wakimoto et al, 1996).
The IL-2 gene has been introduced into TILs via a retroviral
vector to improve IL-2 delivery into the tumour. A recent phase I
study used this approach in ten patients with advanced NSCLC
with pleural effusion who showed some improvement in the
pleural effusions (Tan et al. 1996).
Targeting the tumour by in vivo gene therapy is another option
that at present is only feasible by local intratumoral delivery. It is
likely that in the next 10 years progress in gene delivery systems
will allow in vivo gene targeting after i.v. injection of the vector.
One option is todelivergenescoding forimmunostimulatory mole-
cules such as IL-2 (Tursz et al. 1996). Another option is to correct
genetic abnormalities in tumourcells. Roth et al. (1996) have deliv-
ered a retroviral vector containing the wild-type p53 gene directly
into p53-mutated NSCLC tumours in nine patients with advanced
disease. Wild typep53 regulates the progression ofcells in the cell
cycle fromGI to the S-phase. Mutation ofp53 isusualy a late event
in lung cancer and leads to uncontrolled growth of cancer cells.
Reintroduction of the dominant wild-type (unmutated gene) can
revert this process. Roth et al (1996) observed tumour regression
and apoptosis in the tumours of some treated patients. Another
option is to introduce a gene whose product converts a non-toxic
pro-drug to a toxic compound. Herpes simplex virus thymidine
kinase (HSV-TK) in combination withendogenous TKphosphoryl-
ates the pro-drug gancyclovir (GCV) to toxic gancyclovir triphos-
phate (GCV-PPP). Interestingly, GCV-PPP can enter untransfected
neighbouring tumour cells through communicating gap junctions.
and this leads to death of non-expressing HSV-TK cells (local
bystander effect). This is important as only a small proportion
(20%) of the cells in a tumour need to express HSV-TK to bring
about 100% of tumour cell death. An inflammatory raction in
response to the cell death with accumulation of type-I cytokines
fiuther increases the bystander effect by boosting local and
systemic immunological recognition of the tumour cells (Freeman
et al. 1997). Recently, this approach has been used in the treatment
of pleural mesothelioma in rats. HSV-TK expressing adenoviral
vectors were injected directly intrapleurally with significant reduc-
tion in tumour burden (Elshami et al. 1996). Human studies are
on-going (Treat et al. 1996).
Another approach is to use anti-idiotypic antibodies. These anti-
bodies are raised against monoclonal antibodies recognizing cell-
surface tumour antigen and have a similar shape to the tumour
antigen. This approach is currently the focus of an EORTC trial
(SIILVA study) that uses an anti-idiotype BEC2 (anti-idiotype to
ganglioside GD3) combined with BCG adjuvant in SCLC. A pilot
study (Grant et al, 1996) using BEC2/BCG in patients with SCLC
showed minimal toxicity, with median survival not reached after
15 months. which compares favourably with historic controls.
CONCLUSION
Overall outcome from standard treatments for lung cancer remains
poor. Immunotherapy could have an important role to play in the
treatment of lung cancer. Active specific vaccination is safe to
administer and available data suggest beneficial effect in the adju-
vant setting; recent advances in tumour antigen characterization
and gene therapy will aid the design ofmore effective vaccines.
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